Pancreatic Cancer Research Program Translational Research Partnership Award

The FY22 PCARP Translational Research Partnership Award supports partnerships (3-5 partners) between clinicians and research scientists. Multi-institutional and multi-discipline partnerships are strongly encouraged. At least one partner must have expertise either in pancreatic cancer research or pancreatic cancer patient care.

• Early detection research for pancreatic cancer, including the prevalence in individuals with pre-diabetes and diabetes and/or those in underserved ethnic and minority communities
• Supportive care interventions, patient-reported outcomes, quality of life, and perspectives during treatment and survivorship
• Understanding the relationship between metabolic disruptions in pancreatic cancer and their systemic effects, including diabetes and cachexia
• Understanding precursors, origins, and early progression of pancreatic cancer
• Understanding the events that promote pancreatic cancer metastasis
• Understanding the relationship between oncogenic signaling and the tumor microenvironment that drives drug resistance and therapeutic response
• New drug development targeted toward cancer sensitivity and resistance mechanisms including immune mechanisms of resistance

It is expected that four (4) awards will be granted. 

Funding: $750,000 total

Duration: 3 years 

Research Authority due date: 30.6.22

Pre application (required) due date: 8.7.22

Full proposal due date: 6.10.22